Published in Blood Weekly, November 10th, 2005
In the video, CEO Gary S. Jacob outlines Callisto's drug development programs and describes some of the key anticipated medical and marketplace advantages of the company's two drug candidates, Atiprimod and Annamycin, which are being developed as treatments for relapsed multiple myeloma and relapsed leukemia, respectively. Patients are referred to as "relapsed" when they fail to respond to standard chemotherapy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.